Liffers R
Onkologie. 1981 Jun;4(3):156-61. doi: 10.1159/000214901.
91 patients with malignant non-Hodgkin-lymphoma are discussed, who received a reinduction therapy because of their state of relapse or dissemination. All of them received chemotherapy as a secondary treatment. The drugs were cyclophosphamide, vincristine, methotrexate, and prednisone. The result were separately analyzed for lymphomas with "high-grade malignancy" and lymphomas with "low-grade malignancy" using the "Kiel-Klassifikation". Within the group of low-grade lymphomas, there were 29% complete remission, 56% partial remission, and 15% without response. In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response. The curves of disease-free survival are similar for both groups of malignant low-grade and high-grade lymphoma. The curve for survival, irrespective of exacerbation, takes a more favorable course for low-grade than for high-grade lymphomas but reaches a common plateau at 30%. After 2 1/3 years 50% of the patients with low-grade-malignant lymphoma, and after 1 1/2 year 50% of the patients with high-grade-malignant lymphoma, are still alive. The longest period of disease-free survival is now 8 years in some cases. We attempt to draw conclusions from the results of the therapy about the nature of malignant non-Hodgkin-lymphoma and to give suggestions for its treatment.
讨论了91例恶性非霍奇金淋巴瘤患者，他们因复发或播散状态接受了再诱导治疗。所有患者均接受化疗作为二线治疗。药物包括环磷酰胺、长春新碱、甲氨蝶呤和泼尼松。使用“基尔分类法”分别分析了“高度恶性”淋巴瘤和“低度恶性”淋巴瘤的治疗结果。在低度恶性淋巴瘤组中，完全缓解率为29%，部分缓解率为56%，无反应率为15%。在高度恶性淋巴瘤组中，完全缓解率为39%，部分缓解率为37%，无反应率为24%。低度恶性和高度恶性淋巴瘤两组的无病生存曲线相似。不考虑病情加重的生存曲线，低度恶性淋巴瘤比高度恶性淋巴瘤更有利，但在30%时达到共同平台期。2又1/3年后，50%的低度恶性淋巴瘤患者仍存活，1又1/2年后，50%的高度恶性淋巴瘤患者仍存活。目前，某些病例的最长无病生存期为8年。我们试图从治疗结果中得出关于恶性非霍奇金淋巴瘤性质的结论，并为其治疗提供建议。
